SAN DIEGO, Oct. 27, 2015 /PRNewswire/ -- OncoSec Medical
Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, today issued the
below letter to Company shareholders from CEO and President
Punit Dhillon. For supplemental
proxy materials and additional information regarding the Fiscal
Year 2015 Annual Meeting of Shareholders, please visit OncoSec's
website:
http://oncosec.com/oncosec-issues-annual-letter-to-shareholders.
Dear Valued Shareholder,
As we work to develop new cancer treatments for patients, I
would like to thank you for your ongoing support of OncoSec's
programs and strategies. With your support, we continue to champion
our company's purpose: to deliver safer and more effective cancer
immunotherapies that can make a difference in the lives of
patients. Looking ahead, I would like to provide an overview of our
progress since the last Annual Shareholder Meeting.
OncoSec's clinical development strategy is focused on
demonstrating that ImmunoPulse™ IL-12 is a rational choice for
combination therapy with anti-PD-1 agents. We believe ImmunoPulse™
IL-12 has the ability to convert a significant proportion of
non-responder patients into those who will respond to anti-PD1
agents, and have aligned our clinical pipeline to validate this
hypothesis.
As we advance our clinical pipeline, we are also working to
develop advanced devices capable of accessing difficult-to-reach
tumors, investigating new therapeutic candidates, and exploring
unique combination approaches. We have also finalized plans to move
into a new facility by year's end. Our expanded headquarters will
consolidate clinical, discovery research, and administrative
operations into one well-equipped facility. This move enhances our
development capabilities and provides OncoSec with a base of
operations that matches the magnitude of our ambitions.
To maintain consistent communication with our shareholders, we
are establishing a new cadence for external communications, which
started recently with quarterly conference calls and the timing of
our Annual Shareholder Meeting. Our Annual Shareholder Meeting will
now closely follow the filing of our Annual Report on Form 10-K.
These activities are designed to establish a more regular
communications schedule and further enhance shareholder
engagement.
We encourage all eligible shareholders to vote in accordance
with the information outlined in our definitive proxy statement.
Your vote is especially important to us this year, as we look to
initiate an exciting new program: our 2015 Employee Stock Purchase
Plan. This allows all OncoSec employees to share in our vision by
purchasing stock directly from the Company. We believe this program
will support our progress by ensuring that each member of our team
has a personal stake in OncoSec's success.
We look forward to sharing updates on our upcoming milestones at
our Annual Shareholder Meeting and throughout the year. Thank you
again for your ongoing support and confidence in OncoSec as we
continue to advance our immuno-oncology pipeline.
Sincerely,
Punit Dhillon
CEO and President
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies for the treatment of cancer. The Company's
investigational technology, ImmunoPulse™, is designed to enhance
the local delivery and uptake of DNA-based immune-targeting agents,
such as interleukin-12 (IL-12). In Phase I and II clinical trials,
OncoSec's lead program, ImmunoPulse™ IL-12, demonstrated a
favorable safety profile and evidence of anti-tumor activity in the
treatment of various skin cancers as well as the potential to
initiate a systemic immune response. ImmunoPulse™ IL-12 is
currently in Phase II development for several indications,
including metastatic melanoma, squamous cell carcinoma of the head
and neck, and triple-negative breast cancer. In addition to
ImmunoPulse™ IL-12, the Company is also seeking to identify and
develop new immune-targeting agents for use with the ImmunoPulse™
platform. For more information, please visit www.oncosec.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking
statements regarding future events and the future performance of
OncoSec. Forward-looking statements are subject to risks and
uncertainties, which may cause actual results to differ materially
from current expectations. These risks and uncertainties include,
among others, the following: our ability to raise additional
funding necessary to fund continued operations on reasonable terms
or at all; our ability to protect our intellectual property;
uncertainties inherent in pre-clinical studies and clinical trials,
such as the ability to enroll patients in clinical trials and the
risk of adverse events; delays in the commencement or completion of
clinical testing for product candidates; unexpected new data,
safety and technical issues; our ability to develop and
commercialize the assets we have acquired or develop and any new
assets and product candidates; and competitive, market and
regulatory conditions. Other risks and uncertainties are described
in OncoSec's annual report on Form 10-K filed on October 14, 2015, and subsequent filings with the
U.S. Securities and Exchange Commission made by OncoSec. Except as
required by law, OncoSec undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Contact
Investor Relations:
Jordyn Kopin
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com
Media Relations:
Mary Marolla
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-issues-annual-letter-to-shareholders-300166621.html
SOURCE OncoSec Medical Incorporated